Lv62
2270 积分 2024-12-24 加入
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
1小时前
已完结
Abstract 5857: Trastuzumab deruxtecan resistance can be mediated by payload resistance or secondary extracellular ERBB2 mutations but sensitivity to HER2 tyrosine kinase inhibitors is maintained
19小时前
求助中
Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies
22小时前
已完结
Unlocking the potential of bispecific ADCs for targeted cancer therapy
2天前
已完结
Innovations for Next-Generation Antibody-Drug Conjugates
2天前
已完结
Delivering More Payload (High DAR ADCs)
3天前
已关闭
Fluorogenic monomer activation for protein-initiated atom transfer radical polymerization
3天前
已完结
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice
3天前
已完结
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma
5天前
已完结
911 Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
8天前
已完结
皖公网安备34019202002308
